ATE19792T1 - Verfahren zur herstellung eines kolonspezifischen antigen p tryptischen peptides und von anti-kolon-spezifischen antigen p antikoerpern. - Google Patents

Verfahren zur herstellung eines kolonspezifischen antigen p tryptischen peptides und von anti-kolon-spezifischen antigen p antikoerpern.

Info

Publication number
ATE19792T1
ATE19792T1 AT82104604T AT82104604T ATE19792T1 AT E19792 T1 ATE19792 T1 AT E19792T1 AT 82104604 T AT82104604 T AT 82104604T AT 82104604 T AT82104604 T AT 82104604T AT E19792 T1 ATE19792 T1 AT E19792T1
Authority
AT
Austria
Prior art keywords
colon
specific antigen
antibodies
tryptic peptide
production
Prior art date
Application number
AT82104604T
Other languages
English (en)
Inventor
Milton David Goldenberg
Dan Shochat
Original Assignee
Milton David Goldenberg
Dan Shochat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milton David Goldenberg, Dan Shochat filed Critical Milton David Goldenberg
Application granted granted Critical
Publication of ATE19792T1 publication Critical patent/ATE19792T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT82104604T 1981-06-01 1982-05-27 Verfahren zur herstellung eines kolonspezifischen antigen p tryptischen peptides und von anti-kolon-spezifischen antigen p antikoerpern. ATE19792T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/269,115 US4468457A (en) 1981-06-01 1981-06-01 Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
EP82104604A EP0066786B1 (de) 1981-06-01 1982-05-27 Verfahren zur Herstellung eines Kolon-spezifischen Antigen P tryptischen Peptides und von anti-Kolon-spezifischen Antigen P Antikörpern

Publications (1)

Publication Number Publication Date
ATE19792T1 true ATE19792T1 (de) 1986-05-15

Family

ID=23025864

Family Applications (1)

Application Number Title Priority Date Filing Date
AT82104604T ATE19792T1 (de) 1981-06-01 1982-05-27 Verfahren zur herstellung eines kolonspezifischen antigen p tryptischen peptides und von anti-kolon-spezifischen antigen p antikoerpern.

Country Status (9)

Country Link
US (1) US4468457A (de)
EP (1) EP0066786B1 (de)
JP (1) JPS58501355A (de)
AT (1) ATE19792T1 (de)
AU (1) AU550306B2 (de)
CA (1) CA1183451A (de)
DE (1) DE3271119D1 (de)
IL (1) IL65915A (de)
WO (1) WO1982004263A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
DE3432714A1 (de) * 1984-09-06 1986-04-24 Behringwerke Ag, 3550 Marburg Tumortherapeutikum und verfahren zu seiner herstellung
US4962187A (en) * 1984-11-28 1990-10-09 Cota Biotech Common antigen for colorectal and mucinous ovarian tumors and process for isolating the same
DK172686A (da) * 1985-04-22 1986-10-23 Hybritech Inc Antigen opnaaet ud fra humant vaev, fremgangsmaade til under anvendelse af antigenet at fremstille monoklonale antistoffer til diagnose og behandling af cancer, fremgangsmaade til paavisning af cancer, samt antistoffer mod antigenet
ES8800604A1 (es) * 1985-04-22 1987-11-16 Hybritech Inc Un metodo para producir anticuerpos monoclonales
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
DK169987D0 (da) * 1987-04-03 1987-04-03 Jens Christian Jensenius Human tumor-associated antigen, ca-ou1
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
ATE303160T1 (de) * 1993-08-11 2005-09-15 Jenner Technologies Impfstoff gegen prostatakrebs
US7011812B1 (en) * 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US6458933B1 (en) 1998-05-20 2002-10-01 Immunomedics, Inc. Therapeutic using a bispecific antibody
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7833528B2 (en) * 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
MX340559B (es) 1999-12-06 2016-07-14 Board Of Trustees Of The Univ Of Illinois Proteinas de tcr de alta afinidad y metodos.
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US7166719B2 (en) 2002-06-27 2007-01-23 Health Research, Inc. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy
EP1351712B1 (de) * 2000-06-20 2007-08-01 Immunomedics, Inc. Zielgerichtete kombinationsimmuntherapie für krebs und infektionskrankheiten
AU2002220275A1 (en) * 2000-12-08 2002-06-18 The Board Of Trustees Of The University Of Illinois Mutated class ii major histocompatibility proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ATE335515T1 (de) * 2001-03-30 2006-09-15 Univ Massachusetts Morpholinobildgebung und therapie
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7053210B2 (en) 2002-07-02 2006-05-30 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
CN1767860A (zh) 2003-01-31 2006-05-03 免疫医疗公司 施用治疗和诊断剂的方法和组合物
US7057100B2 (en) * 2003-06-26 2006-06-06 The J.C. Robinson Seed Co. Inbred corn line W23129
US8038983B2 (en) * 2003-07-29 2011-10-18 Immunomedics, Inc. Fluorinated carbohydrate conjugates
PT1733056E (pt) 2004-03-31 2013-08-29 Gen Hospital Corp Método para determinar a responsividade do cancro a tratamentos visando o receptor do factor de crescimento epidérmico
EP2308967B1 (de) * 2004-04-12 2017-08-23 Catalyst Biosciences, Inc. Mutante mt-sp1 polypeptide
US20050260131A1 (en) * 2004-05-20 2005-11-24 General Electric Company Pharmaceuticals for enhanced delivery to disease targets
ES2460517T3 (es) 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
EP2674440B1 (de) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Polyvalente bioaktive anordnungen auf immunglobulinbasis
EP2418223A3 (de) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Einkettige, multivalente Bindungsproteine mit Effektorfunktion
JP4546578B2 (ja) 2006-07-05 2010-09-15 カタリスト・バイオサイエンシーズ・インコーポレイテッド プロテアーゼスクリーニング方法およびそれにより同定されるプロテアーゼ
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
ES2738700T3 (es) 2009-02-13 2020-01-24 Immunomedics Inc Inmunoconjugados con un enlace escindible intracelularmente
US8012770B2 (en) 2009-07-31 2011-09-06 Invisible Sentinel, Inc. Device for detection of antigens and uses thereof
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
CN102612555A (zh) 2009-10-09 2012-07-25 因威瑟堡善迪诺有限公司 用于检测抗原的装置及其应用
ES2745140T3 (es) 2011-01-27 2020-02-27 Invisible Sentinel Inc Dispositivos de detección de analitos, dispositivos multiplex y de sobremesa para la detección de analitos y usos de los mismos
US9745631B2 (en) 2011-12-20 2017-08-29 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
AU2013230917C1 (en) 2012-03-09 2021-09-16 Invisible Sentinel, Inc. Methods and compositions for detecting multiple analytes with a single signal
WO2013177426A2 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
US20150285802A1 (en) 2012-07-18 2015-10-08 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
CN104684926B (zh) 2012-07-27 2022-04-08 伊利诺伊州大学理事会 工程化t细胞受体
EP2885002A4 (de) 2012-08-14 2016-04-20 Ibc Pharmaceuticals Inc Umleitung t-zell-bispezifischer antikörper zur behandlung von krankheiten
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9931412B2 (en) 2013-02-08 2018-04-03 The Regents Of The University Of Michigan Targeted theranostics
CA3112661A1 (en) 2013-08-19 2015-02-26 Abbott Molecular Inc. Nucleotide analogs
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
AU2014352834B2 (en) 2013-11-22 2019-08-29 Fred Hutchinson Cancer Research Center Engineered high-affinity human T cell receptors
US10350264B2 (en) 2014-03-27 2019-07-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
JP6841772B2 (ja) 2015-02-17 2021-03-10 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 前立腺癌の処置におけるカバジタキセルの使用
EP3316885B1 (de) 2015-07-01 2021-06-23 Immunomedics, Inc. Antikörper-sn-38-immunkonjugate mit einem cl2a-linker
MX2018003292A (es) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
US10836774B2 (en) 2016-11-30 2020-11-17 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
ES2953032T3 (es) 2017-09-01 2023-11-07 Univ East Carolina Métodos ex vivo para la activación de las células inmunológicas
WO2020236818A1 (en) 2019-05-20 2020-11-26 Nirvana Sciences Inc. Narrow emission dyes, compositions comprising same, and methods for making and using same
ES3036313T3 (en) 2019-05-20 2025-09-17 Nirvana Sciences Inc Narrow emission dyes, compositions comprising same, and methods for making and using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2719102A (en) * 1949-10-28 1955-09-27 Corn States Serum Company Clostridium perfringens toxoid and process of making the same
US4086217A (en) * 1976-03-03 1978-04-25 Hoffmann-La Roche Inc. Carcinoembryonic antigens
US4228236A (en) * 1978-05-15 1980-10-14 Northwestern University Process of producing carcinoembryonic antigen

Also Published As

Publication number Publication date
EP0066786A3 (en) 1983-07-20
JPS58501355A (ja) 1983-08-18
DE3271119D1 (en) 1986-06-19
IL65915A0 (en) 1982-08-31
US4468457A (en) 1984-08-28
WO1982004263A1 (en) 1982-12-09
EP0066786A2 (de) 1982-12-15
IL65915A (en) 1985-07-31
AU8731882A (en) 1982-12-07
CA1183451A (en) 1985-03-05
EP0066786B1 (de) 1986-05-14
AU550306B2 (en) 1986-03-13

Similar Documents

Publication Publication Date Title
ATE19792T1 (de) Verfahren zur herstellung eines kolonspezifischen antigen p tryptischen peptides und von anti-kolon-spezifischen antigen p antikoerpern.
KR900009095A (ko) 합성 항원, 이의 제조방법 및 용도
ES8305419A1 (es) Un peptido
ES2006941A6 (es) Un metodo de producir un peptido o una proteina relacionados con un epitope de virus asociado a linfoadenopatiasnvirus de leucemia de celulas t humanas (lavnhtlv-iii).
DE69110663D1 (de) Verfahren zur herstellung eines enzymhydrolysates.
DE69434811D1 (de) Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen
DK0461177T3 (da) Humant intra-acrosomalt spermantigen til anvendelse i en svangerskabsforebyggende vaccine
AU8172094A (en) Synthetic HTLV-III peptides, compositions and uses thereof
SE8205313L (sv) Antigen-proteinkomplex for blockering av allergiska reaktioner samt sett for framstellning derav
DE3788229D1 (de) Verfahren zur isolierung von ca 125-antigen.
DE69101281D1 (de) Tieftemperatur-Lufttrennung zur Erzeugung von druckerhöhtem Produktgas.
KR840009069A (ko) 향정신성 펩티드류의 제조 방법
SE8103198L (sv) Forfarande for framstellning av antikroppar
ATE5592T1 (de) Verfahren zur herstellung von 4'deoxydaunorubicin und 4'-deoxydoxorubicin, sowie 4'-epi-4'-trifluormethyl-sulfonyloxy-ntrifluoracetyldaunorubicin.
GB1375811A (de)
NZ331557A (en) Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
JPS5657753A (en) Novel glucagon fragment, and its use
AU612683B2 (en) Synthetic peptides, antibodies directed against them, and the use thereof
NO900758D0 (no) Fremgangsmaate for fremstilling av hybridprotein.
ES443969A1 (es) Procedimiento de preparacion de un agente peptidico de regu-lacion de la glucemia.
ATE91304T1 (de) Verfahren zur herstellung des pres 1/s2/shepatitis-b-antigens aus hefe.
KR840002346A (ko) 펩타이드의 제조방법
SU646162A1 (ru) Способ разделени природного и попутного газов
PT73587A (en) Process for preparing novel peptides
PT79232A (en) Process for producing immune interferon and of pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties